| Stereochemistry | ABSOLUTE |
| Molecular Formula | C18H25ClFN3O6 |
| Molecular Weight | 433.859 |
| Optical Activity | UNSPECIFIED |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Charge | 0 |
SHOW SMILES / InChI
SMILES
CC(C)C(=O)OC[C@@]1(CCl)O[C@H]([C@H](F)[C@@H]1OC(=O)C(C)C)N2C=CC(N)=NC2=O
InChI
InChIKey=MJVKYGMNSQJLIN-KYZVSKTDSA-N
InChI=1S/C18H25ClFN3O6/c1-9(2)15(24)27-8-18(7-19)13(28-16(25)10(3)4)12(20)14(29-18)23-6-5-11(21)22-17(23)26/h5-6,9-10,12-14H,7-8H2,1-4H3,(H2,21,22,26)/t12-,13+,14-,18-/m1/s1
| Molecular Formula | C18H25ClFN3O6 |
| Molecular Weight | 433.859 |
| Charge | 0 |
| Count |
MOL RATIO
1 MOL RATIO (average) |
| Stereochemistry | ABSOLUTE |
| Additional Stereochemistry | No |
| Defined Stereocenters | 4 / 4 |
| E/Z Centers | 0 |
| Optical Activity | UNSPECIFIED |
Lumicitabine (formerly called ALS-8176), a first-in-class orally administered nucleoside analogue is being developed by Alios BioPharma for the treatment of respiratory syncytial virus infections. Lumicitabine converts to plasma-circulating ALS-8112, and then to the 5'-active nucleoside triphosphate (NTP) form within host cells. Extensive and rapid RSV reduction occurred after lumicitabine treatment (EC50 = 1.79 uM), with >99% viral inhibition at 2 h after loading dose. Clinical trials of Lumicitabine for the treatment of respiratory syncytial virus infection are ongoing.
Originator
Approval Year
PubMed
Sample Use Guides
Respiratory Syncytial Virus Infections: Participants will receive ALS-008176, 250 mg oral suspension once on Day 1 under fasted conditions. Participants will receive ALS-008176, 500 mg oral suspension once on Day 1 under fasted conditions. Participants will receive ALS-008176, 750 mg oral suspension once on Day 1 under fasted conditions.
Route of Administration:
Oral
